1-戊基-3-(金刚烷-1-甲酰基)吲哚 | 1345973-49-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-戊基-3-(金刚烷-1-甲酰基)吲哚
• 英文名称: 1-pentyl-N-tricyclo[3.3.1.1]dec-1-yl-1H-indole-3-carboxamide
• 英文别名: adamantan-1-yl(1-pentyl-1H-indol-3-yl)methanone；3-[(adamantan-1-yl)carbonyl]-1-pentylindole；1-Pentyl-3-(1-adamantoyl)indole；1-adamantyl-(1-pentylindol-3-yl)methanone
• CAS: 1345973-49-0
• 化学式: C₂₄H₃₁NO
• 分子量: 349.516
• InChiKey: SHWDYCMMUPPWQM-UHFFFAOYSA-N

物化性质

• 密度：
  1.21
• 溶解度：
  DMF：30mg/mL； DMSO：30mg/mL；乙醇：1mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-金刚烷甲酸 在 草酰氯 、 二甲基氯化铝 、 N,N-二甲基甲酰胺 作用下， 以 正己烷 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 1-戊基-3-(金刚烷-1-甲酰基)吲哚
  参考文献：
  名称：

  The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse

  摘要：

  Two novel adamantane derivatives, adamantan-1-yl (1-pentyl-1H-indo1-3-yl) methano ne (AB-001) and N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide (SDB-001), were recently identified as cannabimimetic indoles of abuse. Conflicting anecdotal reports of the psychoactivity of AB-001 in humans, and a complete dearth of information about the bioactivity of SDB-001, prompted the preparation of AB-001, SDB-001, and several analogues intended to explore preliminary structure-activity relationships within this class. This study sought to elucidate which structural features of AB-001, SDB-001, and their analogues govern the cannabimimetic potency of these chemotypes in vitro and in vivo. All compounds showed similar full agonist profiles at CB1 (EC50 = 16-43 nM) and CB2 (EC50 = 29-216 nM) receptors in vitro using a FLIPR membrane potential assay, with the exception of SDB-002, which demonstrated partial agonist activity at CB2 receptors. The activity of AB-001, AB-002, and SDB-001 in rats was compared to that of Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and cannabimimetic indole JWH-018 using biotelemetry. SDB-001 dose-dependently induced hypothermia and reduced heart rate (maximal dose 10 mg/kg) with potency comparable to that of Delta(9)-tetrahydrocannabinol (Delta(9)-THC, maximal dose 10 mg/kg), and lower than that of JWH-018 (maximal dose 3 mg/kg). Additionally, the changes in body temperature and heart rate affected by SDB-001 are of longer duration than those of Delta(9)-THC or JWH-018, suggesting a different pharmacokinetic profile. In contrast, AB-001, and its homologue, AB-002, did not produce significant hypothermic and bradycardic effects, even at relatively higher doses (up to 30 mg/kg), indicating greatly reduced potency compared to Delta(9)-THC, JWH-018, and SDB-001.

  DOI：

  10.1021/cn400035r

文献信息

• IMMUNOASSAY FOR SYNTHETIC CANNABINOIDS OF THE ADAMANTYL INDAZOLE/INDOLE-3-CARBOXAMIDE FAMILY
  申请人：Randox Laboratories Limited

  公开号：US20150346227A1

  公开（公告）日：2015-12-03

  An immunoassay method for detecting and determining adamantane substituted indazole and indole synthetic cannabinoids is described. Also described are components for use in implementing the method, namely, antibodies, detection agents, solid state devices and kits as well as immunogens used to raise the antibodies.

  本文描述了一种用于检测和确定取代了金刚烷的吲唑和吲哚合成大麻素的免疫测定方法。还描述了用于实施该方法的组分，即抗体、检测试剂、固态设备和试剂盒，以及用于制备抗体的免疫原。
• Immunoassay for synthetic cannabinoids of the adamantyl indazole/indole-3-carboxamide family
  申请人：Randox Laboratories Limited

  公开号：US10591497B2

  公开（公告）日：2020-03-17

  An immunoassay method for detecting and determining adamantane substituted indazole and indole synthetic cannabinoids is described. Also described are components for use in implementing the method, namely, antibodies, detection agents, solid state devices and kits as well as immunogens used to raise the antibodies.

  描述了一种用于检测和确定金刚烷取代的吲唑和吲哚合成大麻素的免疫测定方法。还描述了用于实施该方法的组件，即抗体、检测剂、固态装置和试剂盒以及用于提高抗体的免疫原。
• ACS Chem. NACS Chem. Neurosci. 2013, 4, 1081-1092
  作者：

  DOI：——

  日期：——
• The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse
  作者：Samuel D. Banister、Shane M. Wilkinson、Mitchell Longworth、Jordyn Stuart、Nadine Apetz、Katrina English、Lance Brooker、Catrin Goebel、David E. Hibbs、Michelle Glass、Mark Connor、Iain S. McGregor、Michael Kassiou

  DOI：10.1021/cn400035r

  日期：2013.7.17

  Two novel adamantane derivatives, adamantan-1-yl (1-pentyl-1H-indo1-3-yl) methano ne (AB-001) and N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide (SDB-001), were recently identified as cannabimimetic indoles of abuse. Conflicting anecdotal reports of the psychoactivity of AB-001 in humans, and a complete dearth of information about the bioactivity of SDB-001, prompted the preparation of AB-001, SDB-001, and several analogues intended to explore preliminary structure-activity relationships within this class. This study sought to elucidate which structural features of AB-001, SDB-001, and their analogues govern the cannabimimetic potency of these chemotypes in vitro and in vivo. All compounds showed similar full agonist profiles at CB1 (EC50 = 16-43 nM) and CB2 (EC50 = 29-216 nM) receptors in vitro using a FLIPR membrane potential assay, with the exception of SDB-002, which demonstrated partial agonist activity at CB2 receptors. The activity of AB-001, AB-002, and SDB-001 in rats was compared to that of Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and cannabimimetic indole JWH-018 using biotelemetry. SDB-001 dose-dependently induced hypothermia and reduced heart rate (maximal dose 10 mg/kg) with potency comparable to that of Delta(9)-tetrahydrocannabinol (Delta(9)-THC, maximal dose 10 mg/kg), and lower than that of JWH-018 (maximal dose 3 mg/kg). Additionally, the changes in body temperature and heart rate affected by SDB-001 are of longer duration than those of Delta(9)-THC or JWH-018, suggesting a different pharmacokinetic profile. In contrast, AB-001, and its homologue, AB-002, did not produce significant hypothermic and bradycardic effects, even at relatively higher doses (up to 30 mg/kg), indicating greatly reduced potency compared to Delta(9)-THC, JWH-018, and SDB-001.